Literature DB >> 24034518

Influence of the 3K3A-activated protein C variant on the plasma clot lysis activity of t-PA and of t-PA on the variant's anticoagulant activity.

L O Mosnier1, J A Fernández, T P Davis, B V Zlokovic, J H Griffin.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24034518      PMCID: PMC3850769          DOI: 10.1111/jth.12400

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  14 in total

Review 1.  The cytoprotective protein C pathway.

Authors:  Laurent O Mosnier; Berislav V Zlokovic; John H Griffin
Journal:  Blood       Date:  2006-11-16       Impact factor: 22.113

2.  Alteplase for acute stroke revisited: the first 10 years.

Authors:  Patrick D Lyden; Kennedy R Lees; Stephen M Davis
Journal:  Lancet Neurol       Date:  2006-09       Impact factor: 44.182

Review 3.  Regulation of fibrinolysis by thrombin activatable fibrinolysis inhibitor, an unstable carboxypeptidase B that unites the pathways of coagulation and fibrinolysis.

Authors:  Laurent O Mosnier; Bonno N Bouma
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-09-07       Impact factor: 8.311

4.  Preclinical safety and pharmacokinetic profile of 3K3A-APC, a novel, modified activated protein C for ischemic stroke.

Authors:  Patricia D Williams; Berislav V Zlokovic; John H Griffin; Kent E Pryor; Thomas P Davis
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

5.  Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C.

Authors:  Dong Liu; Tong Cheng; Huang Guo; José A Fernández; John H Griffin; Xiaomei Song; Berislav V Zlokovic
Journal:  Nat Med       Date:  2004-10-31       Impact factor: 53.440

6.  Anti-inflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke.

Authors:  M Shibata; S R Kumar; A Amar; J A Fernandez; F Hofman; J H Griffin; B V Zlokovic
Journal:  Circulation       Date:  2001-04-03       Impact factor: 29.690

7.  Activated protein C mutant with minimal anticoagulant activity, normal cytoprotective activity, and preservation of thrombin activable fibrinolysis inhibitor-dependent cytoprotective functions.

Authors:  Laurent O Mosnier; Xia V Yang; John H Griffin
Journal:  J Biol Chem       Date:  2007-09-14       Impact factor: 5.157

8.  Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective.

Authors:  Tong Cheng; Dong Liu; John H Griffin; José A Fernández; Francis Castellino; Elliot D Rosen; Kenji Fukudome; Berislav V Zlokovic
Journal:  Nat Med       Date:  2003-02-03       Impact factor: 53.440

9.  Neuroprotective activities of activated protein C mutant with reduced anticoagulant activity.

Authors:  Huang Guo; Itender Singh; Yaoming Wang; Rashid Deane; Theresa Barrett; José A Fernández; Nienwen Chow; John H Griffin; Berislav V Zlokovic
Journal:  Eur J Neurosci       Date:  2009-03       Impact factor: 3.386

10.  Activated protein C prevents neuronal apoptosis via protease activated receptors 1 and 3.

Authors:  Huang Guo; Dong Liu; Harris Gelbard; Tong Cheng; Rae Insalaco; José A Fernández; John H Griffin; Berislav V Zlokovic
Journal:  Neuron       Date:  2004-02-19       Impact factor: 17.173

View more
  5 in total

1.  Improved coagulation and haemostasis in haemophilia with inhibitors by combinations of superFactor Va and Factor VIIa.

Authors:  Vikas Bhat; Annette von Drygalski; Andrew J Gale; John H Griffin; Laurent O Mosnier
Journal:  Thromb Haemost       Date:  2015-10-15       Impact factor: 5.249

2.  3K3A-Activated Protein C Variant Does Not Interfere With the Plasma Clot Lysis Activity of Tenecteplase.

Authors:  Purba Mukherjee; Patrick Lyden; José A Fernández; Thomas P Davis; Kent E Pryor; Berislav V Zlokovic; John H Griffin
Journal:  Stroke       Date:  2020-06-17       Impact factor: 7.914

3.  Phase 1 safety, tolerability and pharmacokinetics of 3K3A-APC in healthy adult volunteers.

Authors:  Patrick Lyden; Howard Levy; Sara Weymer; Kent Pryor; William Kramer; John H Griffin; Thomas P Davis; Berislav Zlokovic
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

Review 4.  Stroke Treatment With PAR-1 Agents to Decrease Hemorrhagic Transformation.

Authors:  Patrick D Lyden; Kent E Pryor; Jennifer Minigh; Thomas P Davis; John H Griffin; Howard Levy; Berislav V Zlokovic
Journal:  Front Neurol       Date:  2021-03-15       Impact factor: 4.003

Review 5.  Phase I and Phase II Therapies for Acute Ischemic Stroke: An Update on Currently Studied Drugs in Clinical Research.

Authors:  Cesar Reis; Onat Akyol; Wing Mann Ho; Camila Araujo; Lei Huang; Richard Applegate; John H Zhang
Journal:  Biomed Res Int       Date:  2017-02-14       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.